Trial Profile

Dose tapering and Early Discontinuation to InCreAse cosT-effectIveness Of immunotherapy for Non-small cell lung carcinoma trial number 1

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 02 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary)
Indications Mesothelioma; Non-small cell lung cancer
Focus Therapeutic Use
Acronyms Dedication-1

Most Recent Events

15 Aug 2020 Planned number of patients changed from 117 to 750.
15 Aug 2020 Protocol amended to change study drug from Pemetrexed to pembrolizumab. Planned number of patients, primary end point were changes as reported by European Clinical Trials Database record.
06 Sep 2018 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com